Skip to content

Clinical evaluation of betamethasone combined with ramosetron in the prevention of nausea and vomiting caused by moderate emetic risk chemotherapy regimens

Clinical evaluation of betamethasone combined with ramosetron in the prevention of nausea and vomiting caused by moderate emetic risk chemotherapy regimens

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078577
Enrollment
Unknown
Registered
2023-12-13
Start date
2023-12-13
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor, Chemotherapy induced nausea and vomiting

Interventions

Betamethasone with Ramosetron Group:Betamethasone
Dexamethasone with Ramosetron Group:Dexamethasone

Sponsors

The People's hospital of Jianyang City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: ? Age = 18 years old, ECOG PS score 0-2; ? diagnosed with malignant tumors using histological or cytological methods; ?receiving chemotherapy for the first time; ? Accept moderate emetic risk chemotherapy regimens, including oxaliplatin containing chemotherapy regimens, irinotecan containing chemotherapy regimens, nedaplatin containing chemotherapy regimens, etc; ? Hematology, liver and kidney function, and important organ function indicators meet the requirements of chemotherapy; ? For female patients, the pregnancy test should be negative, and sufficient contraceptive measures should be taken throughout the entire study period; ? Sign informed consent forms.

Exclusion criteria

Exclusion criteria: ? Mental disability or emotional disorders; ? Receive radiotherapy during the trial period; ? Receive the investigational drug 5 days prior to trial admission; ? Nausea and vomiting appeared 24 hours before treatment; ? Currently undergoing anti epileptic treatment; ? Long term hormone users (including those with immune system diseases such as systemic lupus erythematosus, adrenal cortex dysfunction, etc.); ? Taboos for using 5-HT3 RA, dexamethasone, and betamethasone; ? Primary or metastatic central nervous system tumors; ? Pregnant or lactating women; ? The researchers consider that it is not suitable for participants.

Design outcomes

Secondary

MeasureTime frame
The incidence of complete delayed response 24 to 120 hours after chemotherapy;Overall satisfaction of subjects with treatment after 120 hours of chemotherapy;the Functional Living Index-Emesis after 120 hours of chemotherapy;adverse events;

Primary

MeasureTime frame
The incidence of complete acute reactions within the first 24 hours after chemotherapy;

Countries

China

Contacts

Public ContactRui Qiu

The People's hospital of Jianyang City

569251922@qq.com+86 158 8240 5960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026